SCHEMBL4389760

SCHEMBL4389760

COc1cccc(C)c1-n1c(C)cc(O)cc1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 3/20 0.54
CYP19A1 P11511 1/20 0.41
NQO2 P16083 1/20 0.41
ANPEP P15144 1/20 0.38
DPP4 P27487 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 3/20 0.38
MAPK14 Q16539 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 2/20 0.37
ATM Q13315 1/20 0.37
BCAT1 P54687 2/20 0.37
POLH Q9Y253 1/20 0.36
BCAT2 O15382 1/20 0.36
ALDH1A1 P00352 2/20 0.36
ELANE P08246 1/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4381208 0.86 ANPEP (0.45) APLNRANPEPDPP4SMN1; SMN2L3MBTL1
SCHEMBL4377591 0.80 APLNR (0.48) APLNRCYP19A1NQO2SMN1; SMN2L3MBTL1
SCHEMBL4376341 0.74 MAPK14 (0.42) APLNRSMN1; SMN2L3MBTL1MAPK14POLB
SCHEMBL1865239 0.68 NPSR1 (0.48) POLBGAAALDH1A1
SCHEMBL4383585 0.68 MAPT (0.46) SMN1; SMN2MAPTMAPK14POLBGAA
SCHEMBL4507491 0.68 MIF (0.54) MAPTPOLB
SCHEMBL24759465 0.66 SCN9A (0.40) APLNRTSHRMAPTPOLBGAA
SCHEMBL4376841 0.66 ALDH1A1 (0.60) SMN1; SMN2L3MBTL1TSHRMAPK14POLB
SCHEMBL8343534 0.66 APLNR (0.43) APLNRCYP19A1NQO2SMN1; SMN2L3MBTL1
SCHEMBL24418764 0.65 ALDH1A1 (0.58) APLNRSMN1; SMN2L3MBTL1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 APLNR 3686/4885CYP19A1 2327/4885NQO2 590/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 APLNR 3374/4885CYP19A1 2050/4885NQO2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.